Reglitazar

Reglitazar, an isoxazolidine-3,5-dione derivative, is being developed by Pfizer for the treatment of diabetes. It is the first non-thiazolidenedione to enter clinical trials. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Reglixane and Reglitazar (JAN/INN). Its PubChem CID is 154000.

CAS No 170861-63-9
Molecular Formula C22H20N2O5
Molecular Weight 392.4 g/mol
Synonyms 4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,2-oxazolidine-3,5-dione

Frequently Asked Questions